| 臺大學術典藏 |
2021-03-03T03:01:44Z |
HBsAg in placentas
|
Ho-Hsiung Lin; HO-HSIUNG LIN |
| 臺大學術典藏 |
2020-02-17T08:51:17Z |
HBsAg in placentas
|
HO-HSIUNG LIN |
| 臺大學術典藏 |
2018-09-10T08:04:10Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu, M.-L. and Lee, C.-M. and Chuang, W.-L. and Lu, S.-N. and Dai, C.-Y. and Huang, J.-F. and Lin, Z.-Y. and Hu, T.-I. and Chen, C.-H. and Hung, C.-. and Wang, J.-H. and Chen, C.-L. and Kao, J.-H. and Lai, M.-Y. and Liu, C.-H. and Su, T.-H. and Wu, S.-S. and Liao, L.-Y. and Kuo, H.-T. and Chao, Y.-C. and Tung, S.-Y. and Yang, S.-S. and Chen, P.-J. and Liu, C.-J. and Chen, D.-S.; CHUN-JEN LIU; PEI-JER CHEN; CHEN-HUA LIU; TUNG-HUNG SU; DING-SHINN CHEN; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-03-09T01:47:46Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; Kao J.-H.; Lai M.-Y.; Liu C.-H.; TUNG-HUNG SU; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; Liu C.-J.; Chen D.-S. |
| 臺大學術典藏 |
2021-05-24T07:20:50Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; Kao J.-H.; Lai M.-Y.; CHEN-HUA LIU; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; Liu C.-J.; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T06:12:14Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; JIA-HORNG KAO; Lai M.-Y.; Liu C.-H.; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; Liu C.-J.; Chen D.-S. |
| 臺大學術典藏 |
2022-01-25T05:10:33Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; CHI-LING CHEN; Kao J.-H.; Lai M.-Y.; Liu C.-H.; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; Liu C.-J.; Chen D.-S. |
| 臺大學術典藏 |
2022-01-24T09:31:58Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; Kao J.-H.; Lai M.-Y.; Liu C.-H.; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; CHUN-JEN LIU; Chen D.-S. |
| 臺大學術典藏 |
2021-07-03T03:34:42Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; Kao J.-H.; Lai M.-Y.; Liu C.-H.; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; PEI-JER CHEN; Liu C.-J.; Chen D.-S. |
| 國立臺灣大學 |
2009 |
Hbsag Seroclearance: The More and Earlier, the Better
|
曾岱宗; 高嘉宏; TSENG, TAI-CHUNG; KAO, JIA-HORNG |
| 臺大學術典藏 |
2018-09-10T07:39:49Z |
HBsAg Seroclearance: The More and Earlier, the Better
|
Tseng, Tai-Chung;Kao, Jia-Horng; JIA-HORNG KAO; TSENG, TAI-CHUNG; KAO, JIA-HORNG |
| 臺大學術典藏 |
2021-09-04T06:12:30Z |
HBsAg Seroclearance: The More and Earlier, the Better
|
Tseng T.; JIA-HORNG KAO |
| 臺大學術典藏 |
2021-06-24T06:46:54Z |
HBsAg, HBsAb, immunoglobulins and C3 in primary nephrotic syndrome
|
WAN-YU CHEN; Chuang C.Y.; Chen D.S.; Wang T.H.; Yen T.S.; Hsieh B.S.; Lin M. |
| 高雄醫學大學 |
2011 |
HBsAg-seropositive Advanced Hepatocellular Carcinoma Patients with Everolimus, a mTOR inhibitor, therapy: Change of Serum HBV DNA Titer and Hepatitis Flare-up
|
戴嘉言;夏和雄;張俊彥;莊萬龍;陳立宗 |
| 元智大學 |
2005-10 |
HBT nonlinear current characterization for Volterra analysis
|
陳冠宇; 黃建彰 |
| 元智大學 |
2005-10 |
HBT nonlinear current characterization for Volterra analysis
|
陳冠宇; 黃建彰 |
| 國立交通大學 |
2014-12-13T10:29:48Z |
HBT 電晶體小訊號Pi模型之解析式的解法
|
胡樹一; Hu Shu-I |
| 元智大學 |
2004 |
HBT元件非線性現象分析與HBT元件應用在Wireless LAN802.11a之設計
|
陳冠宇; Kuan-Yu Chen |
| 高雄醫學大學 |
2000 |
hBUB1在骨髓性急性白血病之表現
|
林勝豐;林柏每;楊名琦;劉大智;張建國;蘇裕傑;陳田柏 |
| 高雄醫學大學 |
2000 |
hBuB1基因在惡性血液疾病之突變分析
|
蘇裕傑;林柏每;劉大智;張建國;陳田柏;林勝豐 |
| 國立臺灣大學 |
2015 |
HBV cure-can we pin our hopes on immunotherapy?
|
Yang, Hung-Chih; Kao, Jia-Horng; 高嘉宏; 楊宏志 |
| 國立臺灣大學 |
1994 |
HBV DNA in Cell Lines and Nude Mouse-Passaged Tissues Derived from Human Hepatoma
|
陳美如; Chou, M. J.; 張權維; Chen, J. Y.; Yang, C. S.; Chen, Mei-Ru; Chou, M. J.; Chang, Chein-Wei; Chen, J. Y.; Yang, C. S. |
| 國立臺灣大學 |
1994-02 |
HBV DNA in Cell Lines and Nude Mouse-Passaged Tissues Derived from Human Hepatoma
|
Chen, Mei-Ru; Chou, M. J.; Chang, Chein-Wei; Chen, J. Y.; Yang, C. S. |
| 國立臺灣大學 |
1994-02 |
HBV DNA in Cell Lines and Nude Mouse-Passaged Tissues Derived from Human Hepatoma
|
Chen, Mei-Ru; Chou, M. J.; Chang, Chein-Wei; Chen, J. Y.; Yang, C. S. |
| 國家衛生研究院 |
2023-04-17 |
HBV DNA integration into telomerase or MLL4 genes and TERT promoter point mutation as three independent signatures in subgrouping HBV-related HCC with distinct features
|
Li, CL;Hsu, CL;Lin, YY;Ho, MC;Chen, CL;Ho, TC;Lin, YF;Tsai, SF;Tzeng, ST;Huang, CF;Wang, YC;Yeh, SH;Chen, PJ |
